Analyst Price Targets — DFTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 16, 2026 8:22 pm | Paul Matteis | Stifel Nicolaus | $30.00 | $22.46 | TheFly | Definium Therapeutics initiated with a Buy at Stifel |
| April 16, 2026 10:20 am | Sumant Kulkarni | Canaccord Genuity | $38.00 | $22.15 | TheFly | Definium Therapeutics price target raised to $38 from $25 at Canaccord |
| April 10, 2026 10:59 am | — | Piper Sandler | $49.00 | $21.55 | TheFly | Definium Therapeutics initiated with an Overweight at Piper Sandler |
| February 23, 2026 9:17 pm | — | Wolfe Research | $25.00 | $16.95 | TheFly | Definium Therapeutics initiated with an Outperform at Wolfe Research |
| January 29, 2026 11:29 pm | — | Jefferies | $30.00 | $17.24 | TheFly | Definium Therapeutics initiated with a Buy at Jefferies |
| January 29, 2026 12:40 pm | — | Robert W. Baird | $37.00 | $16.84 | TheFly | Definium Therapeutics price target raised to $37 from $16 at Baird |
| January 23, 2026 7:25 pm | — | RBC Capital | $36.00 | $17.40 | TheFly | Definium Therapeutics price target raised to $36 from $20 at RBC Capital |
| October 13, 2025 9:56 am | Ami Fadia | Needham | $28.00 | $11.81 | TheFly | Mind Medicine initiated with a Buy at Needham |
| March 7, 2025 12:35 pm | — | Robert W. Baird | $16.00 | $6.83 | TheFly | Mind Medicine price target lowered to $16 from $27 at Baird |
| September 16, 2024 8:07 am | Sumart Kulkami | Canaccord Genuity | $14.00 | $6.45 | StreetInsider | MindMed (MNMD) PT Lowered to $14 at Canaccord Genuity |
Latest News for DFTX
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to…
Definium Therapeutics, Inc. is maintained at a Strong Buy due to imminent 2026 catalysts and robust late-stage pipeline progress. DFTX expects three pivotal data readouts in 2026 from phase 3 trials of DT120 ODT for GAD and MDD, plus phase 2a data for DT402 in ASD. DT402 targets a large unmet need in adult ASD, leveraging a differentiated R(-)-MDMA profile with prior phase 1 safety validation.
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences and events: 25th Annual Needham Virtual Healthcare…
Definium Therapeutics, Inc. (NASDAQ: DFTX - Get Free Report) has been assigned a consensus rating of "Buy" from the twelve brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two have issued a strong buy recommendation on the company. The
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world prevalence, incidence, and burden of GAD in the United States healthcare system from 2020 to 2023. These findings show a steadily increasing diagnosed prevalence of GAD and highlight a…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DFTX.
U.S. House Trading
No House trades found for DFTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.